Source
Patient-derived route
Personal iPS-derived EV is discussed as a patient-derived and traceable-source route, not as a multiple-donor product.
iPS-Derived EV
Understand iPS first, then review EV separately.
iPS cells come from research on reprogramming mature cells toward a pluripotent state. iPS-derived EV is different: it does not mean iPS cells themselves are placed into the body. EVs are small particles released by cells. For personal iPS-derived EV, patients should review source, traceability, particle count, size distribution, purification, quality documents, and physician explanation.
Research Background
Reprogramming is the background, not a promise.
The 2012 Nobel Prize in Physiology or Medicine was awarded for the discovery that mature cells can be reprogrammed toward pluripotency. This background helps patients understand the term “iPS”, but it does not mean a person becomes younger or that an EV-related option will produce a specific outcome.
Personal iPS Route
Personal iPS is not a same-day product.
Personal iPS creation may take about six months, followed by approximately two additional months if iPS-derived EV manufacturing is considered. Actual timing depends on sampling, infection screening, creation status, quality confirmation, storage, and shipment timing.
Particle
Count and size
Particle count and size distribution are review items. They do not prove clinical effect or absence of risk.
Process
Recovery and filtering
Ask how EVs are recovered, purified, filtered, stored, and transported, and what documents are supplied.
Review
Physician explanation
The physician explains known points, unknown points, unapproved-use boundaries where relevant, alternatives, risks, costs, and follow-up.
This page is consultation preparation. It does not claim rejuvenation, cancer prevention, cartilage regeneration, absence of risk, or a specific result.